Vysis
This article was originally published in The Gray Sheet
Executive Summary
Firm is developing automated FISH (fluorescence in situ hybridization) gene-probe technology instrument in conjunction with Mercer Scientific International, Downers Grove, Illinois-based Vysis reports Oct. 29. Slated for release in the first quarter of 1999, the system will consist of a re-engineered version of an existing Carl Zeiss automated slide stainer. Under two separate deals, Mercer assumes manufacturing responsibilities while Carl Zeiss agrees to distribute the system and provide customer maintenance and service
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.